Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460399 | 0.86 | KCNH2 (0.55) | KCNH2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5702234 | 0.82 | OPRM1 (0.49) | KCNH2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5461404 | 0.82 | KCNH2 (0.44) | KCNH2ABCB1 | |
| SCHEMBL5464120 | 0.82 | KCNH2 (0.61) | KCNH2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5464013 | 0.82 | PDE10A (0.41) | KCNH2GRIN2BABCB1 | |
| SCHEMBL5454953 | 0.81 | ALDH1A1 (0.48) | OPRM1OPRD1OPRK1OPRL1GRIN2B | |
| SCHEMBL5457685 | 0.79 | ABCB1 (0.49) | KCNH2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5468561 | 0.78 | KCNH2 (0.64) | KCNH2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5468877 | 0.76 | KCNH2 (0.55) | KCNH2OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL5455127 | 0.76 | KCNH2 (0.42) | KCNH2GRIN2BABCB1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | PFIZER, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021414-A1 | 1-'2-(4-Hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists | GRIN1, GRIN3A, GRIN2C | KCNH2 163/4885OPRM1 21/4885OPRD1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.